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Background: Multidrug resistance (MDR) mediated by the overexpression of adenosine 
triphosphate (ATP)-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), 
remains one of the major obstacles to effective cancer chemotherapy. In this study, lipid/ 
particle assemblies named LipoParticles (LNPs), consisting of a dimethyldidodecylammonium 
  bromide (DMAB)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticle core surrounded 
by a 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) shell, were specially designed for 
  anticancer drugs to bypass MDR in human breast cancer cells that overexpress P-gp.
Methods: Doxorubicin (DOX), a chemotherapy drug that is a P-gp substrate, was conjugated 
to PLGA and encapsulated in the self-assembled LNP structure. Physiochemical properties of 
the DOX-loaded LNPs were characterized in vitro. Cellular uptake, intracellular accumulation, 
and cytotoxicity were compared in parental Michigan Cancer Foundation (MCF)-7 cells and 
P-gp-overexpressing, resistant MCF-7/adriamycin (MCF-7/ADR) cells.
Results: This study found that the DOX formulated in LNPs showed a significantly increased 
accumulation in the nuclei of drug-resistant cells relative to the free drug, indicating that LNPs 
could alter intracellular traffic and bypass drug efflux. The cytotoxicity of DOX loaded-LNPs 
had a 30-fold lower half maximal inhibitory concentration (IC50) value than free DOX in 
MCF-7/ADR, measured by the colorimetric cell viability (MTT) assay, correlated with the 
strong nuclear retention of the drug.
Conclusion: The results show that this core-shell lipid/particle structure could be a promising 
strategy to bypass MDR.
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Introduction
The development of multidrug resistance (MDR) is a major obstacle to effective 
  cancer chemotherapy. After a long period of chemotherapy, many patients suffer from 
MDR, which can reduce therapy efficiency and lead to treatment failure.1 The high 
level of resistance is usually caused by complex MDR mechanisms. Among them, 
  overexpression of the adenosine triphosphate (ATP)-binding cassette transporters 
(ABC), such as P-glycoprotein (P-gp), is one of the most prevalent mechanisms.2,3 
Tumor cells possess highly ordered internal resistance. This P-gp encoded by the 
MDR-1 gene acts as a drug efflux pump that exports a wide range of   chemotherapeutic 
drugs and will reduce the accumulation of functional drugs in MDR cancer cells, 
resulting in low cancer chemotherapeutic efficacy.4 Currently, only a few tissue-
derived advanced cancers can be cured by chemotherapeutic drugs. Furthermore, 
these tumors may also recur and become drug resistant.5 Therefore, overcoming the 
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drug resistance of tumors is a serious challenge for success-
ful chemotherapy.
With the development of nanotechnology, nanoformula-
tions have been widely used to circumvent MDR.6,7 Previous 
studies have shown that these nano-sized particles, such as 
lipids, micelles, and inorganic hybrid particles, can bypass the 
P-gp efflux pumps and alter the intracellular accumulation of 
chemotherapeutic drugs.8,9 In a recent study, biodegradable 
polymer capsules offered a promising means to circumvent 
P-gp-mediated MDR.10 The capsules were internalized 
by MDR cells via endocytosis, and were designed for the 
subsequent intracellular release of the drugs by enzymatic 
degradation in lysosomes. According to another strategy, 
low molecular weight polyethylenimine (PEI) conjugated to 
doxorubicin (DOX)-loaded particles could escape endosomal 
retention, and increase the intracellular DOX accumulation, 
thereby circumventing MDR-mediated drug efflux.11 These 
synthetic biomaterials are able to escape the endosomal/
lysosomal compartment and change intracellular traffick-
ing to increase the drug concentration in MDR cancer cells. 
These are common mechanisms whereby MDR activity 
can be reversed. Thus, various endosomal escape pathways 
provide an opportunity for encapsulating drugs to overcome 
MDR in tumors.12
Several synthetic agents that have been introduced, such 
as PEI and poly(amidoamine)s (PAAs), have the proton 
sponge effect, a property that can contribute to efficient 
endosomal escape.13,14 In this study, dimethyldidodecylam-
monium bromide (DMAB), which is a cationic emulsifier 
with double hydrocarbon chains, was used to escape the 
endosomal pathway. Early nanotechnology application of 
DMAB focused on oral drug delivery or inhibition of vascular 
restenosis because of its low critical micelle concentration 
and high zeta potential.15,16 Recent studies have shown that 
DMAB-modified nanoparticles are an ideal vehicle for 
nuclear targeting that could significantly improve the trans-
fection rate in gene delivery.17 The results demonstrated 
clearly that DMAB-modified nanoparticles could evade the 
arrest of the endosomal/lysosomal lumen and destabilize 
the membranes. This is similar to the effects elicited by the 
lysosomal disrupting agent L-Leucine-L-leucine methyl ester 
(LLME).18 The carrier then escapes from the endosomes/
lysosomes and is targeted to the cell nucleus. These and 
other studies with drug- or gene-loaded DMAB nanoparticles 
have demonstrated their advantage as efficient drug delivery 
vehicles with small particles sizes, enhanced cell uptake, and 
endosomal escape.19,20 However, no studies have been   carried 
out to improve the biocompatibility of DMAB particles for 
in vivo applications, or to examine whether drug-loaded 
DMAB particles are able to circumvent MDR by efficiently 
escaping endosomes and lysosomes.
In recent years, the core-shell supramolecular   structures, 
the lipid/particle assemblies – termed LipoParticles (LNPs) –   
have received considerable attention for their potential 
  application in biomedicine and biotechnology.21,22 These 
LipoParticles assemblies, based on electrostatic interac-
tion, were first reported by Carmona-Ribeiro et al.23,24 
Later, Troutier et al reported an in-depth characterization 
on the basis of zeta potential measurements and micro-
scopic morphology.25,26 Subsequent studies demonstrated 
that these unique hybrid assemblies, consisting of a solid 
polymer sphere surrounded by a lipid shell, could combine 
the advantages of lipid shells with those of solid support 
cores.27 The lipid shell provides excellent biocompatibility, 
as well as the ability to encapsulate particles for in vitro 
and in vivo bioapplications for protein, peptide, and DNA 
(lipidic liposome/DNA complexes) delivery.28 Lipid/particle 
assemblies, based on cationic polysaccharide nanoparticles 
as oligonucleotide carriers, appear to be endocytosed and 
accumulate intracellularly in the cytoplasm, further indicat-
ing additional structural advantages.29
The current study designed a novel, core-shell structure 
lipid/particle assembly, LNPs, based on the cationic DMAB-
modified poly(lactic-co-glycolic acid) (PLGA) nanopar-
ticles to overcome MDR. The PLGA nanoparticle core was 
wrapped by 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) via hydrophilic and electrostatic interactions and 
forming a stable, cell-like structure.30 Moreover, the phos-
pholipid surface was expected to improve biocompatibility 
and enhance the penetration of barriers. DOX, a cell cycle 
toxic drug, was conjugated to PLGA, as reported previously.31 
In this manner, DOX was loaded in a stable manner, and the 
drug release could also be controlled. The core-shell LNP 
utilizes DMAB-modified DOX-PLGA nanoparticles as a 
strategy to escape the endosomal/lysosomal pathway by 
enzymatic degradation to overcome MDR in cancer cells.10 
The mechanism for reversing MDR was confirmed by intra-
cellular accumulation observations.
Materials and methods
Materials
PLGA block copolymer (50:50, molecular weight: 8000) was 
purchased from Shandong Institute of Medical   Instruments 
(Jinan, China). DPPC was purchased from Avanti Polar 
  Lipids Inc (Alabaster, AL). DOX was purchased from Haikou 
Manfangyuan Chemical Company (Haikou, China). DMAB, 
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Trinton® X-100, and thiazolyl blue tetrazolium   bromide was 
obtained from Sigma-Aldrich®   Chemical Co, (St Louis, 
MI). Ethyl acetate (EA, analytical grade) and acetonitrile 
(high-performance liquid chromatography (HPLC) grade) 
was from Merck (Darmstadt, Germany). Distilled water, 
Milli-Q® (18 MΩ; Millipore, Billerica, MA), was used in 
the synthesis. All other materials were analytical grade. 
Fetal bovine serum (FBS), RPMI-1640 medium (RPMI), 
penicillin-streptomycin (PS, 10000 U/mL), trypsin-EDTA 
solution (0.5% trypsin, 5.3 Mm EDTA tetrasodium), and 
Hank’s balanced salt solution (HBSS) were obtained from 
Gibco® BRL (Gaithersberg, MD).
Preparation of LNPs
DOX-PLGA conjugate was synthesized as reported, and was 
used to prepare nanoparticles. Nanoparticles were prepared 
by the emulsification-diffusion method. In detail, 200 mg 
PLGA-DOX conjugate was dissolved in 10 mL ethyl acetate. 
Then, the oil phase was slowly added into 20 mL of an aque-
ous solution containing 0.5% DMAB, and emulsified using 
a high speed homogenizer (FLUKO, Shanghai, China) twice 
at 10,000 r/min for 10 minutes, 5 minutes each time. The 
resulting oil-in-water emulsion solution was slowly poured 
into 100 mL water under the moderate magnetic stirring. The 
organic solvents were removed through rotary-evaporation. 
The formed nanoparticles were collected by centrifuga-
tion (J2-MC; Beckman Coulter, Fullerton, CA; 51,000 g, 
30   minutes, 4°C) and washed with distilled water for three 
times. The nanoparticle pellet was resuspended in solution 
for further study. Blank nanoparticles were also prepared by 
the same method. DPPC was dissolved in chloroform; the 
solution was incubated at 40°C for 4 hours with backflow 
device; then chloroform was removed by rotary evaporation. 
A suspension of DMAB-modified nanoparticles was added 
to the DPPC lipid membranes. After stirring and 30 minutes 
incubation at 45°C, the suspension was homogeneous with 
Nuclepore™ 100 nm (Whatman®, Brentford, UK). The 
suspension was centrifuged (16,000 g, 30 minutes, 4°C) 
and washed with distilled water three times. The pellet was 
resuspended in solution or freeze-dried for further study.
Nanoparticle characterization
Particle size and size distribution
Mean hydrodynamic diameters and mean size distributions 
were determined at 25°C by means of dynamic-light scat-
tering technique with particle size analyzer (Zetasizer Nano 
S90; Malvern Instruments, Malvern, UK). The measurement 
angle was 90°. The nanoparticle samples were freeze-dried 
and dispersed in a 1 mmol ⋅ L−1 NaCl solution or serum-
supplemented RPMI-1640, and the results was given by the 
average of three measurements. The polydispersity index 
(PDI) was a dimensionless measure of size distribution, and 
was also recorded at this stage.
Surface charge
Zeta potential is an indicator of surface charge, which deter-
mines particle stability in dispersion. Zeta potential was 
performed on a zeta potential analyzer (90Plus; Brookhaven 
Instrument Corp, Huntsville, NY) by the same treatment as 
size measurement.
Transmission electron microscopy
Transmission electron microscopy (TEM) images were 
  performed on a JEM-1230 electron microscope (JEOL, 
Tokyo, Japan) at an acceleration voltage of 80 kV . To prepare 
sample sections of bare particles or polymeric nanoparticles, 
the samples were diluted with phosphate-buffered saline 
(PBS) (NaOH 29 mM, KH2PO4, 50 mM, pH 7.0) and the final 
particle concentration was 1 mg/mL. The resulting sample 
was dropped on to a copper grid. Excess aqueous solution was 
blotted with filter paper and evaporated at room temperature 
for 2 hours before observation.
Scanning electron microscopy
Morphology of the nanoparticles was performed on a field 
emission-scanning electron microscopy (FE-SEM) (S-4800 
UHR; Hitachi High Technologies, Tokyo, Japan). The 
sample was freeze-dried and fixed on metallic studs with 
double-sided conductive tape. It was then precoated with 
platinum before SEM observation.
Loading efficiency of nanoparticles
Untrapped drugs were removed by centrifugation. The 
  nanoparticle samples were freeze-dried. Then 3 or 4 mL 
of nanoparticles or polymeric nanoparticles were dissolved 
in 10 mL dimethylformamide (DMF) solution. The drug 
  concentration was determined by HPLC (Agilent 1100; 
Hewlett Packard HP/Agilent Technologies, Santa Clara, CA). 
The drug loading content (LC) was calculated.
Drug release
DOX-loaded polymeric nanoparticles 5 mL were diluted into 
1 mL 1/15 M PBS (pH 5.5, 6.5, and 7.4), in a dialysis bag 
of MW 3500 (Boya Biotechnology, Shanghai, China). The 
dialysis bags containing samples were placed into 20 mL PBS, 
37°C incubator shaker at 150 r/min. At appropriate intervals, 
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5.0 mL solution was removed for determination by HPLC, and 
fresh release medium was replaced immediately. Percent drug 
released from polymeric nanoparticles was calculated.
P-gp expression
MCF-7 cells and MCF-7/ADR cells were allowed to grow 
in 25 mL cell bottles separately for 72 hours. One million 
cells were collected for each sample and were centrifuged 
at 4000 r/min for 3–4 minutes. After washing each sample 
three times by bovine serum albumin (BSA) (0.1 mg/mL), 
P-gp specific primary antibody (Abcam, Cambridge, UK) 
were added and incubated for 1 hour. Then cells were washed 
another three times by BSA (0.1 mg/mL) and fluorescein 
isothiocyanate-labeled secondary antibody (MultiSciences 
Biotech Co, Ltd, Beijing, China) was added. Again 1 hour 
later, cells were washed twice by PBS (pH 7.4) and analyzed 
using flow cytometry (FACS) for the green fluorescence 
intensity. Untreated cells were taken as controls for both cells.
Cellular uptake assay
MCF-7 parental cells and resistant MCF-7/ADR cells were 
obtained from the Institute of Biochemistry and Cell Biology 
of Chinese Academy of Sciences (IBCB, Shanghai, China). 
Cells were cultured in RPMI-1640 medium with 1% penicillin-
streptomycin solution, supplemented with 10% FBS at 37°C, 
5% CO2, and 95% humidity. In the present study, 5 × 104 cells 
were seeded on 24 well black plates (Costar, Acton, MA), 
which were incubated until the cells reached 80% confluence. 
The medium was changed with Hank’s HBSS (pH 7.4) and 
incubated for 30 minutes. After equilibration, the cells were 
incubated with nanoparticle suspension (8 µg/mL free DOX 
or a concentration of LNPs-DOX equivalent to 8 µg/mL 
in HBSS). The samples were incubated with the cells for 
0.50–4 hours at 37°C. Then, the cells were centrifuged and 
washed using PBS (pH 7.4) to eliminate free particles that 
were not preyed by the cells. After washing three times, FACS 
analysis was used to determine DOX intensity. Negative 
control was also determined for regulating the results.
Confocal laser scanning microscopy
Cells were seeded on glass-bottom culture dishes and incu-
bated at 37°C, 5% CO2, and 95% relative humidity. After 
80% confluent, the medium was removed and replaced by 
HBSS. Thirty minutes later, the solution was replaced with 
free DOX, or LNPs-DOX with the same DOX concentration. 
The cells were incubated with particles at 37°C for 4 hours. 
Then the cells were washed three times with PBS (pH 7.4) 
solution to eliminate free particles that were not removed by 
cell uptake. Cells were then fixed with 4% paraformaldehyde 
in PBS for 30 minutes, and nuclei were stained by Hoechst 
33342 (Beyotime Biotechnology, Nanjing, China). The 
samples were examined with the confocal laser scanning 
microscope (LSM 510; Zeiss, Dresden, Germany). The 
excitation wavelengths were 405 nm and 488 nm (Hoechst, 
blue; DOX, red), respectively.
Dose-response experiments
MCF-7 parental cells and resistant MCF-7/ADR cells were 
seeded in 96 well plates at a density of 1 × 104 cells per well 
and incubated for 24 hours. After that, the medium was 
replaced with the specified samples. The cells were then 
treated with free DOX or polymeric nanoparticles at a certain 
concentration of DOX in 150 µL RPMI-1640 medium. Cell 
viability was determined after 24-hour incubation. Thiazolyl 
blue tetrazolium bromide solution was added into each well. 
Without any additions, the cells were incubated at 37°C 
and 5% CO2 for 4 hours. Subsequently, the culture medium 
in each well was removed, and 200 µL dimethyl sulfoxide 
(DMSO) was used to dissolve the formed formazan crystals. 
The absorbance was measured at 570 nm after shaking using 
an enzyme-linked immunosorbent assay (ELISA) plate 
reader (Thermo Scientific Multiskan® Spectrum; Thermo 
Scientific, Waltham, MA). Cells incubated with fresh RPMI-
1640 medium were used as a control.
Statistical analysis
Statistical analysis was performed using t-test. Differences 
between groups were designated as P , 0.05(*).
Results
Preparation and characterization of LNPs
In this study, the LNPs were designed for reversing MDR with 
DMAB-modified PLGA nanoparticle (NP) core coated with 
DPPC (Figure 1). DOX and PLGA were connected via an 
amide bond, as reported (supporting information, S1).31 The 
DOX conjugation efficiency was 46% measured by nuclear 
magnetic resonance. This kind of DOX-PLGA conjugate 
could facilitate zero-order release of DOX at the tumor site 
for a long period. PLGA NPs prepared by DMAB dissolved in 
ethyl acetate had a uniform size distribution of about 150 nm. 
The LNPs were self-assembled from the cationic DMAB-
modified PLGA NP core. The PLGA NPs were wrapped in 
DPPC via electrostatic forces, and the size of the formed LNPs 
increased to approximately 200 m. The DOX loading content 
of the PLGA NPs and LNPs was 0.71% ± 0.06% and 0.52% ± 
0.10%, respectively, as measured by HPLC (Table 1).
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The surface morphology of LNPs was studied by means of 
TEM and SEM (Figure 2). Based on TEM images (  Figure 2A 
and B), the LNPs showed relatively uniform sizes and were 
surrounded by a layer of petal-like vesicles with a bilayer 
thickness of about 20 nm. SEM images (Figure 2C and D) 
showed that the surface structure of the PLGA NPs modified 
by DMAB was fairly rigid, and did not show the decomposi-
tion under the effect of electron-beam bombardment. The 
surface of the LNPs showed evidence of degradation and 
cracking under the same voltage conditions. These results 
demonstrate that the nanoparticles were covered by a layer 
of DPPC.32 PLGA NPs had a high positive zeta potential of 
57 mV owing to the cationic DMAB. The surface proper-
ties of the PLGA core should be changed with the DPPC 
coating, and the zeta potential of LNPs was reduced from 
57 mV to −1.8 mV (Table 1). This negative zeta potential 
may improve the biocompatibility and facilitate further 
application in vivo.33 The colloidal stability of PLGA NPs and 
LNPs was determined in serum-supplemented RPMI-1640 
by dynamic-light scattering. Compared to PLGA NPs, the 
LNPs showed excellent stability in this biomimetic medium 
over a 7-day period.
In vitro drug release
Drug release in vitro was determined in PBS of different pH 
(5.5, 6.5, and 7.4) to estimate the potential drug release char-
acteristics of the nanoparticles under different physiological 
conditions. The release profiles revealed that the release of 
DOX from LNPs-DOX (with lipid shell, LC 0.52%) was 
accelerated at low pH. As shown in Figure 3, the LNPs-
DOX released its drug more readily at pH 5.5, 6.5, and 7.4. 
The LNPs with a lipid shell exhibited less than 20% DOX 
release after the first 6 hours at pH 7.4 (blood pH level), 
and approximately 32% slow leakage within 72 hours. This 
controlled release from LNPs-DOX was similar to that from 
NPs-DOX (without a lipid shell; supporting information S2), 
and indicates that aggregation proceeds independent of the 
spatial structure of the particle core and the lipid shell, and 
that the DOX release was affected more by the DOX-PLGA 
conjugation. In the more acidic tumor microenvironment 
(pH 6.5), and in endosomes/lysosomes (pH 5.5), DOX release 
from these assemblies was more rapid, suggesting that DOX 
can be released sharply during intracellular trafficking, which 
would be helpful to bypass drug efflux.
Determination of MDR  
on MCF-7/ADR cells
Parental MCF-7 and resistant MCF-7/ADR cells were pur-
chased from ICBC, and maintained at 37°C in 5% CO2 in 
RPMI-1640 medium with a 1% penicillin-streptomycin 
solution. Preliminary experiments and the MTT assays here 
showed that MCF-7/ADR had significant MDR. MCF-7 
and MCF-7/ADR cells were exposed to increasing doses 
of DOX for 24 hours. Cell viability and 50% viability 
(IC50) were determined (supporting information, S3). The 
IC50 of MCF-7/ADR (47.53 ± 2.53 µg/mL) was 228-fold 
greater than that in MCF-7 cells (0.221 ± 0.045 µg/mL). 
To further understand the drug resistance in MCF-7/ADR, 
P-gp protein expression was determined by flow   cytometry. 
The results revealed that the greater drug resistance of 
MCF-7/ADR was accompanied by the higher expression 
of P-gp protein (Figure 4), suggesting that reversal of 
resistance to DOX in MCF-7/ADR should escape this 
protein-mediated efflux.
Table  1  Physicochemical  properties  of  different  formulations   
(n = 3)
Sample Size (nm) ZP (mV) PDI LC (%)
PLgA-NPs 150 ± 10.7 57.1 ± 1.6 0.106 ± 0.027 0.71 ± 0.06
LNPs 195 ± 27.2 −1.8 ± 1.0 0.159 ± 0.072 0.52 ± 0.10
Abbreviations:  ZP,  zeta  potential;  PDI,  polydispersity  index;  LC,  loading 
content; PLgA-NPs, doxorubicin-loaded PLgA nanoparticles; LNPs, lipid/polymer 
particle assemblies.
LNP
Figure 1 Schematic diagram showing the structure of lipid/polymer particle assemblies. 
The negative phosphate charges on the hydrophilic segment of DPPC (green) can be 
attracted to the oppositely charged ions of the ammonium bromide ammonia headgroup 
of DMAB (blue), which modify the surface of DOX-loaded PLgA nanoparticles (red).
Abbreviations:  DMAB,  dimethyldidodecylammonium  bromide;  DOX,  doxorubicin; 
DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; LNP, lipid/polymer particle assembly; 
PLgA, poly(lactic-co-glycolic) acid.
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Intracellular accumulation of doxorubicin
DOX is known to interact with DNA by intercalation and 
inhibition of macromolecular biosynthesis. One potential 
strategy to reverse DOX resistance in cells is to change the 
intracellular localization of the drug through endocytosis 
using carrier particles.34 When drug-loaded nanocarriers 
enter cells via endocytosis, the particle-associated drugs can 
escape endosomal/lysosomal effect (eg, the proton sponge 
effect elicited by PEI) and increase the localization in the 
cytosol or nucleus of cells.35 Here, to determine if LNPs-
DOX could be accumulated efficiently in the nucleus, the 
intracellular localization of free DOX and LNPs-DOX was 
AB
D C
200 nm 200 nm
500 nm 500 nm
Figure 2 TEM and SEM images of LNPs formed with a core-shell supramolecular structure. A TEM image shows relatively uniform sized LNP particles (A), and a LipoParticle 
revealing its lipid shell thickness (B). A SEM image shows the fairly rigid surface morphology of PLgA particles by the electron-beam bombardment effect (C), and another 
SEM image displays the degradation and cracking of LNPs with a DPPC shell (D).
Abbreviations:  DPPC,  1,2-dipalmitoyl-sn-glycero-3-phosphocholine;  LNPs,  lipid/polymer  particle  assemblies;  SEM,  scanning  electron  microscopy;  TEM,  transmission 
electron microscopy.
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Figure 3 In vitro drug release profiles of DOX-loaded LNPs at different pH (5.5, 6.5, and 7.4) and 37°C.
Abbreviations: DOX, doxorubicin; LNPs, lipid/polymer particle assemblies.
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characterized in both parental MCF-7 and MCF-7/ADR cells. 
LNPs-DOX distribution in MCF-7 and MCF-7/ADR cells 
was visualized after 15 minutes, 1 hour, and 4-hour incuba-
tion (Figure 5). Following treatment in MCF-7/ADR cells, 
little free DOX could diffuse into the nucleus, and most of 
the drug accumulated in the cytoplasm (15 minutes–1 hour). 
Then, the drug uptake and accumulation in MCF-7/ADR 
cells was reduced significantly, which should be the result 
of the efflux of DOX caused by the overexpression of the 
ATP-binding cassette (ABC) transporters (Figure 5A). By 
contrast, the intracellular localization of LNPs-DOX in 
MCF-7/ADR cells was changed. After a 1-hour exposure, 
significant DOX was accumulated in the cytoplasm of the 
parental MCF-7 cells, whereas substantially increased LNPs-
DOX accumulated in the nuclei of the drug-resistant MCF-7/
ADR cells (  Figure 5B). This observation suggests that LNPs, 
as a drug carrier, could change the sub-cellular localization 
of DOX and bypass MDR. The results at 4 hours showed the 
long-term accumulation of LNPs-DOX in the nuclei.
To further characterize the intracellular accumulation 
of DOX, the study determined the DOX concentration in 
MCF-7 and MCF-7/ADR cells (Figure 6). After treatment 
with free DOX (15 minutes drug exposure), the amount of 
drug that accumulated in MCF-7 cells was 2.6-fold greater 
than that in MCF-7/ADR cells. Following a 1-hour expo-
sure to free DOX, the drug concentration in MCF-7/cells 
was about tenfold greater than that in MCF-7/ADR cells, 
the DOX within which were reduced due to active drugs 
efflux. In contrast to free DOX, the accumulation of LNPs-
DOX in MCF-7 and MCF-7/ADR cells were similar after 
MCF-7 MCF-7/ADR
Cell lines
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Figure  4  P-gp  expression  in  MCF-7  and  MCF-7/ADR  cells,  as  shown  by  flow 
cytometry analysis.
Note: **P , 0.01.
Abbreviations:  MCF-7,  Michigan  Cancer  Foundation-7;  MCF-7/ADR,  MCF-7/
adriamycin; P-gp, P-glycoprotein.
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Figure 5 Confocal images of the intracellular accumulation of free DOX and LNPs-
DOX in MCF-7 (A) and MCF-7/ADR (B) cells. Cells were treated with 8 µg/mL free 
DOX or an equivalent concentration of LNPs-DOX for the different time periods as 
indicated. Nuclear (blue) uptake of DOX was increased dramatically by LNPs.
Abbreviations:  DOX,  doxorubicin;  free  DOX,  free  doxorubicin;  LNPs-DOX, 
doxorubicin loaded in lipid/polymer particle assemblies; MCF-7, Michigan Cancer 
Foundation-7; MCF-7/ADR, MCF-7/adriamycin.
15 minutes drug exposure. After a 4-hour exposure, the 
LNPs-DOX concentration indicated no significant reduc-
tion in both cells. The phenomenon may demonstrate that 
the LNPs-DOX have successfully bypassed the enzymatic 
degradation and efflux pumps effect. More importantly, based 
on confocal laser scanning microscopy (Figure 5B), most of 
the DOX was located in the nuclei of the cancer cells at this 
time point. Since DOX is a drug that is toxic to the cell cycle 
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DOX-loaded LNPs, blank LNPs, and free DOX to parental 
and resistant MCF-7 cells, using the MTT assay. The blank 
LNPs showed no cytotoxicity to either cell line; the viability 
values of MCF-7 and MCF-7/ADR cells were 98% and 97%, 
respectively, at the blank LNPs concentration of 50 mg/mL 
(Figure 7). The LNPs-DOX and free DOX both exhibited 
significant cell growth inhibition of the parental cell line. 
The DOX-loaded LNPs exhibited a dose-dependent cyto-
toxicity against MCF-7/ADR cells (IC50:1.61 ± 0.13µg/ml). 
That is, DOX-loaded LNPs had a 30-fold lower IC50 value 
than free DOX in MCF-7/ADR, suggesting that LNPs can 
circumvent drug efflux-mediated MDR.
Discussion
Adsorption of lipids onto oppositely charged surfaces 
or particles has been studied in detail by analytical and 
simulation methods.36 The study employed lipid/particle 
assemblies composed of positively charged PLGA nanopar-
ticles (150 nm in diameter), covered by a bilayer of DPPC 
(200 nm for LNPs). In this context, DMAB consists of a 
bromide headgroup with two hydrophobic tails connecting 
them together; that is, one hydrophobic chain of DMAB is 
adsorbed onto the surface of PLGA nanoparticles; and the 
other acts as electrostatic glue that enhances the stability of 
the self-assembled particles by molecular electronegativity 
interaction with the oppositely charged phosphocholine 
headgroups.25 Once these cell-like structures were formed, 
the adsorption of a lipid bilayer on the PLGA core could be 
seen by TEM. Based on SEM, the surface of the particles 
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by inhibiting the activity of topoisomerase II, the cytotoxicity 
of LNPs-DOX would be increased.
Reversal of MDR in vitro by LNPs
Following the analysis of the intracellular accumulation of 
LNPs-DOX, the ability of LNPs to overcome MDR was 
investigated. The study evaluated the cytotoxicity in vitro of 
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was covered with DPPC, which constituted a biocompatible 
membrane environment useful for in vivo biomedicine 
(eg, in the delivery of drugs, proteins, and peptides).
LipoParticles are self-assemblies with a particle core 
surrounded by a lipid shell. PLGA particles have certain 
cell cytotoxicity by generating transient holes on cell 
membranes with a positively charged ammonium bromide 
headgroup of the DMAB molecule;37 however, the nega-
tive charges on the hydrophilic segment of DPPC could be 
attracted to the oppositely charged ions of the ammonium 
bromide ammonia headgroup.38 This charge neutralization 
would then form the lipid/particle assemblies, and improve 
the biocompatibility of the particles, with a reduction of the 
zeta potential from 57 mV to −1.8 mV . The MTT assays 
also confirmed that the blank LNPs at 50 mg/mL were not 
cytotoxic, and cell membrane damage caused by DMAB 
was not found. Thus, the modification of the cationic poly-
mer substance with a lipid shell should be a useful means 
to reduce the toxicity of positively charged biomaterials, 
and there is potential to expand the application of these 
materials in biomedicine.
The MDR of MCF-7/ADR was accompanied with 
overexpression of P-gp transporter. Bypassing these drug 
effluxes is a rational strategy to circumvent the MDR.39 In the 
current study, the significant cytotoxicity of LNPs-DOX in 
the MCF-7/ADR has been validated. Overcoming the MDR 
was related to the enhanced intracellular accumulation and 
nuclear targeting of the drug mediated by LNPs. To elaborate 
the details of the MDR reversal, the intracellular accumu-
lation and localization of free DOX and LNPs-DOX was 
investigated in the drug-resistant MCF-7/ADR cells. Since 
the intracellular trafficking pathways of drug-loaded carri-
ers, such as polymer capsules, were previously reported,10 
the cellular uptake and fluorescence imaging studies were 
performed to determine how the newly designed lipid/
particle assemblies were able to bypass the resistance to 
DOX. The results showed that LNPs-DOX could effectively 
increase the DOX concentration in MCF-7/ADR cells, and 
most of the LNPs-DOX located in the nuclei of the drug-
resistant cells after about 1 hour of incubation. This observa-
tion demonstrated that the DMAB-modified particle core had 
the ability to escape from endosomes/lysosomes and localize 
in the nucleus. In summary, when the drug delivery system 
entered cells via endocytosis, after enzymatic degradation, 
the encapsulation of DMAB-modified particle core may be 
exposed to the endosomal/lysosomal lumen, and lead to the 
rupture of the particles.17 Then, the positively charged core 
would deliver the encapsulated DOX to the nucleus, which 
could increase DOX localization in the nucleus, and thereby 
bypass the drug efflux mechanism mediated by transporter 
proteins. The lipid/particle assemblies developed here could 
produce intracellular targeting to the nucleus and overcome 
the resistance of the cancer cells to DOX.
Conclusion
In conclusion, it can be reported that the lipid/particle 
assemblies consisting in DMAB-modified PLGA NPs coated 
with DPPC lipid shell have been successfully developed for 
MDR reversal. The results demonstrate that these LNPs, with 
biomimetic properties of lipids, can improve the biocompat-
ibility of cationic particles via charge neutralization. Impor-
tantly, the LNPs can reverse the transporter-mediated drug 
resistance by increasing the intracellular accumulation and 
improving the targeting to the nucleus. This drug delivery sys-
tem has the potential for overcoming MDR in biomedicine.
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Figure S1 gel Permeation chromatogram of DOX-PLgA conjugate (solid line) and 
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Figure S2 In vitro drug release profiles of DOX-loaded PLGA nanoparticles (without 
DPPC shell) in different pH (5.5, 6.5, and 7.4) at 37°C. Error bars indicate mean ± SD.
Abbreviations: DOX, doxorubicin; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; 
PLgA, poly(lactic-co-glycolic) acid; SD, standard deviation.
Figure S3 Cytotoxicity of Free-DOX against MCF-7 and MCF-7/ADR cells. Error 
bars indicate mean ± SD.
Abbreviations: DOX, doxorubicin; MCF-7, Michigan Cancer Foundation-7; MCF-7/
ADR, MCF-7/adriamycin; SD, standard deviation.
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